

Perrigo Announces Approval to Market Ibuprofen and Pseudoephedrine Tablets

PRNewswire
ALLEGAN, Mich.

The Perrigo Company (NASDAQ: PRGO) today announced that it has received approval to market and distribute Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP, 200 mg and 30 mg respectively, through a development agreement with Ohm Laboratories, Inc., a subsidiary of Ranbaxy Pharmaceuticals Inc. The terms of the agreement provide Perrigo the exclusive right to market and distribute the product in the U.S., Canada and Mexico. Ibuprofen and Pseudoephedrine Hydrochloride Tablets is an over-the-counter drug indicated for the treatment of nasal congestion, headache, fever and body aches and pains. With this approval, the Food and Drug Administration (FDA) has granted 180-day market exclusivity. The product is expected to be available for the 2001/2002 cough and cold season.

Ibuprofen and Pseudoephedrine Hydrochloride Tablets is comparable to the nationally advertised brand Advil® Cold & Sinus produced by Whitehall Laboratories, Inc. Advil® Cold & Sinus is a top brand in the cough and cold category and had sales at retail of approximately \$50 million in 2000.

Perrigo Company is the nation's largest manufacturer of over-the-counter (non-prescription) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by national and regional supermarket, drugstore and mass merchandise chains under their own labels and compete with nationally advertised brands. The Company's products include over-the-counter pharmaceuticals, such as analgesics, cough and cold remedies, antacids, laxatives, feminine hygiene and smoking cessation products, and nutritional products, such as vitamins, nutritional supplements and nutritional drinks. Visit Perrigo on the Internet at <http://www.perrigo.com/> .

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and are subject to the safe harbor created thereby. Please refer to pages 23-27 of the Company's Form 10-K for the year ended July 1, 2000 for a discussion of certain important factors that relate to forward- looking statements contained in this press release. Although the Company believes that the expectations reflected in any such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.

®Advil Cold & Sinus is a registered trademark of American Home Products Corporation.

MAKE YOUR OPINION COUNT - Click Here
<http://tbutton.prnewswire.com/prn/11690X21739568>

SOURCE: Perrigo Company

Contact: Ernest J. Schenk, Manager, Investor Relations and Communication
of Perrigo Company, 616-673-9212, E-mail: Investor@perrigo.com

Website: <http://www.perrigo.com/>

Company News On-Call: <http://www.prnewswire.com/comp/699550.html> or fax,
800-758-5804, ext. 699550

<https://investor.perrigo.com/2001-06-07-Perrigo-Announces-Approval-to-Market-Ibuprofen-and-Pseudoephedrine-Tablets>